Oncology Evolved

Engineering the Next Generation of Off-the-Shelf Cell Therapies

PIPELINE

PRE-CLINICAL

CLINICAL

CAR-T (Allogeneic)

T-ALL/LBL

WU-CART-007

Memory NK (Allogeneic)

AML

WU-NK-101

Solid Tumors

WU-NK-101 + mAb

Solid Tumors

WU-NK-201 Engineered

LATEST NEWS

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies

The Woodlands, TX, and St. Louis, MO, March 14, 2024/ Cision / - Cellipont Bioservices, a leading cell therapy Contract…

Read more
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers…

Read more
OPTIMIZED BY EVOLUTION

Wugen is developing off-the-shelf cellular therapies for cancer

Radio Button Off
About Wugen

Wugen is a clinical-stage biotechnology company

Flask
Science

Cellular therapies originating from healthy donors

People
Careers

Come join our growing teams in San Diego and St. Louis